SCHEMBL5899310

SCHEMBL5899310

Cc1cc(ON2C=Cc3sncc3C2)ccc1NC(=O)Nc1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.51
BRAF P15056 10/20 0.51
RAF1 P04049 2/20 0.51
MAPK3 P27361 1/20 0.51
RIPK2 O43353 1/20 0.43
ABCB11 O95342 1/20 0.43
ABL1 P00519 1/20 0.43
NR3C1 P04150 1/20 0.43
RET P07949 1/20 0.43
HTR1A P08908 1/20 0.43
PDGFRB P09619 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
KIT P10721 1/20 0.43
CHRM1 P11229 1/20 0.43
BCR P11274 1/20 0.43
FGFR1 P11362 1/20 0.43
RARG P13631 1/20 0.43
PDGFRA P16234 1/20 0.43
FLT1 P17948 1/20 0.43
MAOA P21397 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5899271 0.90 CDK8 (0.49) KDRBRAFRAF1PDGFRBKIT
SCHEMBL5899267 0.87 KDR (0.47) KDRBRAFRAF1MAPK3TRPV1
SCHEMBL5899283 0.83 BRAF (0.44) KDRBRAFRETPDGFRBPDGFRA
SCHEMBL5899326 0.77 CA12 (0.46) KDRBRAFRAF1PDGFRBTEK
SCHEMBL5899284 0.75 KDR (0.44) KDRBRAFRAF1RETPDGFRB
SCHEMBL5899288 0.72 KDR (0.47) KDRBRAFRAF1RETPDGFRB
SCHEMBL5899312 0.71 RAF1 (0.63) KDRBRAFRAF1MAPK3RIPK2
SCHEMBL21357139 0.69 BRAF (0.64) KDRBRAFRAF1MAPK3RIPK2
SCHEMBL5899309 0.68 RAF1 (0.53) KDRBRAFRAF1MAPK3RIPK2
SCHEMBL27860285 0.68 KDR (0.85) KDRBRAFRAF1MAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060241301-A1 Urea derivatives and their use as tyrosinkinase inhibitors MERCK PATENT GMBH (DE) 2006-10-26 US claimed
US-20060241301-A1 Urea derivatives and their use as tyrosinkinase inhibitors MERCK PATENT GMBH (DE) 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241301-A1 Urea derivatives and their use as tyrosinkinase inhibitors TIE1, UCK2, UTS2R KDR 45/4885BRAF 34/4885RAF1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.